Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.

6 Jan 2023

Understanding the vector composition of mRNA filled

In this interview, Malvern Panalytical’s Product Technical Specialist, Stefan Cairns, discusses how SEC-SLS can be used to understand MRNA vector composition by referencing his latest publication.

From Malvern Panalytical 19 Dec 2022

XBB Omicron variant evades vaccine-induced immunity

A new study published in The Lancet Microbe examines the immune evasion characteristics of the Omicron XBB subvariant.

12 Dec 2022

New family of adeno-associated viral vectors found to be better at delivering genetic cargo

Gene therapies can treat, even potentially cure, certain genetic diseases, but it is challenging to deliver the treatments to the parts of the body where they are needed.

22 Nov 2022

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

Researchers explored active and passive vaccination among children against respiratory syncytial virus (RSV).

22 Nov 2022

How lessons from the HIV epidemic can help combat COVID-19

Researchers revisit lessons learned from the HIV pandemic in response to COVID-19.

13 Nov 2022

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

In this interview, Niall Dinwoodie, Executive Director for Gene Therapy for Charles River in Europe discusses the opening of their new HQ Plasmid Center of Excellence at Alderley Park.

From Charles River Laboratories, Inc. 4 Nov 2022

COVID-19 vaccines show favorable immunogenicity and efficacy in people living with HIV

In a recent study published in the International Journal of Infectious Diseases, researchers assessed the efficacy of coronavirus disease 2019 (COVID-19) vaccines in people living with human immunodeficiency virus (HIV).

16 Oct 2022

A rare case of Hashimoto encephalopathy after COVID vaccination

In a recent ‘Letter to the Editor’ published in the English edition of the journal Neurologandiacute, researchers reported the rare occurrence of Hashimoto encephalopathy in a recipient of the (COVID-19) vaccine Spikevax. Spikevax, research name mRNA-1273, is a COVID-19 vaccine based on the messenger ribonucleic acid (mRNA) technology.

16 Oct 2022

Transition in the management of COVID-19

A review of the current approaches to managing COVID-19, including diagnostic, therapeutic, and preventive measures.

16 Oct 2022

Review says dose of approved COVID-19 vaccines based on weak evidence

A recent study posted to the medRxiv* preprint server reviewed early-phase dose-finding trials to examine the study design, safety, and early antibody response data on approved coronavirus disease 2019 (COVID-19) vaccines and gain insights on design improvements for future candidate COVID-19 vaccine clinical trials.

26 Sep 2022

Study describes the dynamics of immune responses to triple COVID-19 vaccination

The effectiveness of the three-dose COVID-19 vaccination against SARS-CoV-2 and its variants has been described in detail in a recent study.

23 Sep 2022

Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy.

22 Sep 2022

Is there any impact of COVID-19 vaccines on the fertility of men and women of reproductive age?

Researchers assessed the impact of SARS-CoV-2 vaccines on human fertility.

19 Sep 2022

Exercise hormone irisin blocks Parkinson's-associated α-synuclein aggregation and related neuronal toxicity

A new paper discusses the hope held out by recent results on a compound called irisin, a short protein secreted by skeletal muscle that produces some exercise-related effects on the brain.

15 Sep 2022

Exercise hormone reduces protein levels linked to Parkinson's disease

Researchers from Johns Hopkins Medicine and the Dana Farber Cancer Institute in Boston have shown that a hormone secreted into the blood during endurance, or aerobic, exercise reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice.

12 Sep 2022

Viral Vector News and Research

Further Reading

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

Understanding the vector composition of mRNA filled

XBB Omicron variant evades vaccine-induced immunity

New family of adeno-associated viral vectors found to be better at delivering genetic cargo

Approved and developing passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

How lessons from the HIV epidemic can help combat COVID-19

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

COVID-19 vaccines show favorable immunogenicity and efficacy in people living with HIV

A rare case of Hashimoto encephalopathy after COVID vaccination

Transition in the management of COVID-19

Review says dose of approved COVID-19 vaccines based on weak evidence

Study describes the dynamics of immune responses to triple COVID-19 vaccination

Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

Is there any impact of COVID-19 vaccines on the fertility of men and women of reproductive age?

Exercise hormone irisin blocks Parkinson's-associated α-synuclein aggregation and related neuronal toxicity

Exercise hormone reduces protein levels linked to Parkinson's disease

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

Hybrid immunity retained six months after SARS-CoV-2 exposure

Gene therapy approach delays disease onset in humanized mouse models of familial ALS

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest Life Science News